Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × sacituzumab govitecan × Breast × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 53 Observational 3 Expanded_access 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

veliparib 2 tucatinib 2 abemaciclib 2 Trastuzumab 2 Capecitabine 2 zenocutuzumab 1 selpercatinib 1 sacituzumab govitecan 1 ribociclib 1 pertuzumab 1 pegilodecakin 1 palbociclib 1 margetuximab 1 leronlimab 1 iniparib 1 glembatumumab vedotin 1 gedatolisib 1 eribulin 1 Vinorelbine 1 Proton Pump Inhibitors 1 Letrozole 1 Lapatinib 1 Hydrocortisone 1 Everolimus 1 Cisplatin 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1 AM0010 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04320693 2021-08-19

Expanded Access for IMMU-132

Gilead Sciences

Approved for marketing

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡